MediciNova announces development progress on intranasal formulation of SARS-CoV-2 Vaccine for COVID-19

Among multiple prototypes, company confirmed SARS-CoV-2 specific protein antigen mounted on their membrane surfaces binds with ACE2, which is a known receptor of SARS-CoV-2. They also reported on induction of specific antibodies against SARS-CoV-2 Spike protein in murine study.


Biospace Inc.